Publikace
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Farmaceutická fakulta v Hradci Králové
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Farmaceutická fakulta v Hradci Králové
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Farmaceutická fakulta v Hradci Králové
- Profiling of Tryptophan Metabolic Pathways in the Rat Fetoplacental Unit during Gestation2020 | Farmaceutická fakulta v Hradci Králové
Loading network view...